


- AIDS Clinical Trials Group study A5418
- Opportunity for persons with minimal or mild disease to access treatment and participate in research
 - >65 clinical centers enrolling (1st enrollee September 12, 2022)
 - Fully remote option under development
- Randomized 2:1 to receive drug-vs-placebo for 14 days
 - If evidence of disease progression after 5 days, can receive tecovirimat
- People who are at higher risk for severe disease because of their age or their medical history will be assigned to receive open-label tecovirimat for 14 days

Source: <https://actnetwork.org/studies/a5418-study-of-tecovirimat-for-human-monkeypox-virus-stomp/> Slide 45

22



Question-and-Answer Session

23